Dr Elisabeth Chroni is a Professor of Neurology and Head of Neuromuscular Unit in University Hospital of Patras, Greece. Her main research interests include clinical and neurophysiological aspects of neuromuscular diseases, particularly neuromuscular junction diseases, autoimmune neuropathies, hereditary myopathies and motor neuron diseases.
She was elected representative of Myasthenia Branch of Hellenic Neurological Society for 2016-17 as well as a representative of Hellenic Neurological Society in peripheral neuropathies and clinical neurophysiology. In addition, she serves on Scientific Panels of European Academy of Neurology for since 2015. She is the head of a committee responsible for the development of a national registry of ALS patients.
Her teaching experience includes undergraduate course to medical students, postgraduate lessons to neurology trainees, participation in postgraduate structural programs in the Universities of Athens, Greece and Uppsala, Sweden.
She is the author of 152 peer reviewed articles in international journals (total IF 430, Citations 2850). She has been involved 8 international multi-center studies (phase II & III) on neuromuscular diseases as Principal Investigator and as a collaborator in 4 Funded Clinical Trials (1991-1994 in the U.K and 2012-2016 in Greece). She has been invited to present her work at 59 national/international meetings and has chaired 40 national scientific sessions. She has done work as a reviewer in 37 International Scientific Journals / Member of Editorial Board in 3 journals. Finally, she has served as member of organizing committees of 5 national meetings.
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of ALS but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.